BCIQ Profiles

Company Profile Report
BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.
0305 QT COVID
BioCentury & Getty Images

Regulation

March 5 COVID Quick Takes: Lilly mAbs clear EU hurdle; plus Adaptive authorization, Takeda pushes vaccine ahead in Japan, Aerpio therapy out of I-SPY  

Mar 6, 2021 | 1:45 AM GMT

EMA’s CHMP recommended use of bamlanivimab from AbCellera Biologics Inc. (NASDAQ:ABCL) and Eli Lilly and Co. (NYSE:LLY), alone and together with Lilly’s etesevimab. The committee’s opinion backs use of bamlanivimab and the combo for confirmed COVID-19 in patients aged 12 years and up that do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19.

FDA authorizes Adaptive T cell test for COVID-19
Adaptive Biotechnologies Corp. (NASDAQ:ADPT) received emergency use authorization (EUA) from FDA for its T-Detect test to detect recent or prior infection with SARS-CoV-2, with the goal of identifying individuals, including Long COVID patients, who cleared the virus without forming antibodies. The TCR sequencing-based test, which was developed via a partnership with Microsoft, launched Feb. 23 as a laboratory-developed test (LDT).

Takeda seeks Japan authorization of Moderna vaccine
Moderna Inc. (NASDAQ:MRNA) said that partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) submitted an NDA to Japan’s Ministry of Health, Labour and Welfare (MHLW) to import and distribute Moderna’s vaccine candidate against COVID-19, mRNA-1273 (TAK-919). The partners expect 50 million doses of the vaccine to be distributed beginning this half, pending licensure.

Aerpio’s razuprotafib dropped from I-SPY
Quantum Leap Healthcare Collaborative, the sponsor of the adaptive I-SPY COVID Trial, will not proceed with further testing of razuprotafib from Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO). The collaborative said it dropped the therapy because of difficulty administering it in the setting of COVID-19, with 30% of patients discontinuing the agent due to disease-related hypotension. There was no indication that the therapy caused the hypotension that led to clinical decline in systolic blood pressure, according to QLHC.

How to gain access

Continue reading with a
two-week free trial.